Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Sequana Medical.

    Client Virtual Booth

    SEQUANA MEDICAL

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Sequana Medical
    Belgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Technologiepark 122 9052, Zwijnaarde
    Telephone
    Telephone
    +32 9 292 8065
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sequanamedical.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/2243173/
    Twitter
    Twitter
    https://twitter.com/sequanamed

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Sequana Medical Announces Three Month Follow-Up Data From MOJAVE Non-randomized Cohort Confirming Dramatic Improvement in Diuretic Response and Virtual ...

    Details:

    DSR 2.0 is a disease-modifying heart failure drug therapy, which is currently being evaluated for the treatment of patients with diuretic-resistant heart failure.


    Lead Product(s): DSR 2.0

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: DSR 2.0

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 25, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Sequana Medical Announces DSMB Approval to Start Randomized MOJAVE Cohort US Phase 1/2a Study of DSR® 2.0 for Treatment of Heart Failure

    Details:

    DSR 2.0 (Direct Sodium Removal) via peritoneal ultrafiltration using Infusate 2.0, is under phase 1/2 clinical trials for treatment of patients with diuretic-resistant heart failure.


    Lead Product(s): DSR 2.0

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: DSR 2.0

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 22, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Sequana Medical announces Positive Data from Non-Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure

    Details:

    DSR 2.0 (icodextrin, dextrose, dapagliflozin) is an implant small molecule drug combination, currently being investigated for heart failure management.


    Lead Product(s): Icodextrin,Dextrose,Dapagliflozin

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: DSR 2.0

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 29, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Sequana Medical Announces Initial Positive Data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for Treatment of Heart Failure Through Breaking Vicious ...

    Details:

    DSR 2.0 therapy (icodextrin) involves the use of the peritoneal cavity for the removal of sodium via diffusion. The body responds by eliminating the associated fluid via osmotic ultrafiltration or urination. It is being investigated for congestive heart failure.


    Lead Product(s): Icodextrin,Dextrose

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: DSR 2.0

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Sequana Medical Announces Positive Results From CHIHUAHUA, Phase 1 Clinical Trial of Second-Generation DSR Product for Congestive Heart Failure

    Details:

    DSR 2.0 therapy involves the use of the peritoneal cavity for the removal of sodium via diffusion. The body responds by eliminating the associated fluid via osmotic ultrafiltration or urination. It is being investigated for congestive heart failure.


    Lead Product(s): DSR 2.0

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: DSR 2.0

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 01, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR Study, Reports Disease-Modifying Profile for Short Term DSR and Provides Business Update

    Details:

    Interim results from ten evaluable patients after completion of intensive DSR 1.0 (alfapump DSR Therapy) period demonstrated that DSR therapy safely, effectively and rapidly eliminated persistent congestion and restored euvolemia, resulting in mean weight loss of 6kg.


    Lead Product(s): Alfapump DSR Therapy,Dapagliflozin

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: DSR 1.0

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 19, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search